Commercial Data Sources for the Biopharma Industry

In the quest for achieving full traceability, the exemption applies to certain trading partners under the Act, and postpones enforcement of final compliance requirements while acknowledging progress and ongoing challenges.

Nicholas Saraceno offers an overview of the legislation and how it impacts the pharma supply chain.

With the implementation of unit-level traceability, the collaboration is expected to provide additional visibility not only within the aseptic manufacturing process, but the entire supply chain overall.

Dave DeJean provides his expert insight on lessons he’s learned from his plethora of time in the industry, along with an outlook on where the pharma supply chain stands in adhering to the Drug Supply Chain Security Act (DSCSA).

With the Nov. 27 deadline fast approaching, is the pharma supply chain ready for full data exchange?

The collaboration is centered around meeting track-and-trace requirements.